Open forum infectious diseases · 2026
Effectiveness of Individualized Autovaccine Immunotherapy in Women With Recurrent Urinary Tract Infections: A Prospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Diaz-Brito Vicens, Sanmartí Montserrat, González-Cuevas Araceli, Cárdenas Antonio, Guerrero Maria Eugenia, Capella Anna, Martínez-Franco Eva, Margarit Montserrat, Agud Anna, Bastaros Juan Maria, Medina Francisco, Moreno Encarna, Álvarez María Carmen, Esteve-Palau Erika
Аннотация
BACKGROUND: Recurrent urinary tract infections (rUTIs) disproportionately affect older women and are frequently driven by nonmodifiable risk factors (nmRFs). This study evaluated the effectiveness, safety, and patient-reported outcomes (PROs) of personalized sublingual immunoprophylaxis in women with rUTIs.
METHODS: Prospective, single-center, noncomparative observational cohort study. Women with rUTIs received a Uromune® autovaccine prepared from inactivated strains isolated from each patient's urine culture (UC). Recurrence episodes and UC results were recorded at baseline and at 3, 9, and 12 months. PROs (daily activity, QAct; emotional distress, QEm) were assessed in a predefined substudy. Longitudinal mixed-effects and population-averaged models evaluated change over time and explored baseline risk factors as effect modifiers.
RESULTS: Of 119 screened women, 100 were enrolled (median [IQR] age: 73 [61-80] years); most presented multiple nmRFs. Median (IQR) rUTI episodes decreased from 4 (3-5) at baseline to 0 (0-2) at 3 months and remained 1 (0-2) and 1 (0-3) at 9 and 12 months (all P < .001). Approximately 40% were UTI-free in each follow-up interval. UC negativity was 50.7% at 3 months, decreased at 9 months (25.9%), and increased again at 12 months (45.5%), remaining higher than baseline. QEm improved significantly at 3 and 12 months; QAct showed a trend toward improvement. Vaccine-related adverse events were uncommon (6%) and mild.
CONCLUSIONS: Individualized sublingual immunoprophylaxis was safe and associated with sustained reductions in rUTI episodes, improved microbiological findings, and better emotional well-being, suggesting a potential role as a nonantibiotic preventive strategy. These observational findings are hypothesis-generating and warrant confirmation in controlled studies.
METHODS: Prospective, single-center, noncomparative observational cohort study. Women with rUTIs received a Uromune® autovaccine prepared from inactivated strains isolated from each patient's urine culture (UC). Recurrence episodes and UC results were recorded at baseline and at 3, 9, and 12 months. PROs (daily activity, QAct; emotional distress, QEm) were assessed in a predefined substudy. Longitudinal mixed-effects and population-averaged models evaluated change over time and explored baseline risk factors as effect modifiers.
RESULTS: Of 119 screened women, 100 were enrolled (median [IQR] age: 73 [61-80] years); most presented multiple nmRFs. Median (IQR) rUTI episodes decreased from 4 (3-5) at baseline to 0 (0-2) at 3 months and remained 1 (0-2) and 1 (0-3) at 9 and 12 months (all P < .001). Approximately 40% were UTI-free in each follow-up interval. UC negativity was 50.7% at 3 months, decreased at 9 months (25.9%), and increased again at 12 months (45.5%), remaining higher than baseline. QEm improved significantly at 3 and 12 months; QAct showed a trend toward improvement. Vaccine-related adverse events were uncommon (6%) and mild.
CONCLUSIONS: Individualized sublingual immunoprophylaxis was safe and associated with sustained reductions in rUTI episodes, improved microbiological findings, and better emotional well-being, suggesting a potential role as a nonantibiotic preventive strategy. These observational findings are hypothesis-generating and warrant confirmation in controlled studies.